Podcast appearances and mentions of timothy showalter

JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, “Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer” . Host Dr. Rafeh Naqash and Dr. Showalter discuss how multimodal AI as a prognostic marker in nonmetastatic castration-resistant prostate cancer may serve as a predictive biomarker with high-risk patients deriving the greatest benefit from treatment with apalutamide. TRANSCRIPT  Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we'll bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast Editor for JCO Precision Oncology and assistant professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are excited to be joined by Dr. Timothy Showalter, Chief Medical Officer at Artera and professor of Radiation Oncology at the University of Virginia and author of the JCO Precision Oncology article entitled, “Digital Pathology Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase 3 Trial in Men with Non-Metastatic Castration Resistant Prostate Cancer.” At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Showalter, it's a pleasure to have you here today. Dr. Timothy Showalter: It's a pleasure to be here. Thanks for having me. Dr. Rafeh Naqash: I think this is going to be a very interesting discussion, not just from a biomarker perspective, but also in terms of how technologies have evolved and how we are trying to stratify patients, trying to escalate or deescalate treatments based on biomarkers. And this article is a good example of that. One of the things I do want to highlight as part of this article is that Dr. Felix Feng is the first author for this article. Unfortunately, Dr. Felix Feng passed away in December of 2024. He was a luminary in this field of prostate cancer research. He was also the Chair of the NRG GU Committee as well as Board of Directors for RTOG Foundation and has mentored a lot of individuals from what I have heard. I didn't know Dr. Feng but heard a lot about him from my GU colleagues. It's a huge loss for the community, but it was an interesting surprise for me when I saw his name on this article as I was reviewing it. Could you briefly talk about Dr. Feng for a minute and how you knew him and how he's been an asset to the field? Dr. Timothy Showalter: Yeah. I'm always happy to talk about Felix whenever there's an opportunity. You know, I was fortunate to know Felix Feng for about 20 years as we met during our residency programs through a career development workshop that we both attended and stayed close ever since. And you know, he's someone who made an impact on hundreds of lives of cancer researchers and other radiation oncologists and physicians in addition to the cancer patients he helped, either through direct clinical care or through his innovation. For this project in particular, I first became involved soon after Felix had co-founded Artera, which is, you know the company that developed this. And because Felix was such a prolific researcher, he was actually involved in this and this research project from all different angles, both from the multimodal digital pathology tool to the trial itself and being part of moving the field forward in that way. It's really great to be able to sort of celebrate a great example of Felix's legacy, which is team science, and really moving the field forward in terms of translational projects based on clinical trials. So, it's a great opportunity to highlight some of his work and I'm really happy to talk about it with you. Dr. Rafeh Naqash: Thanks, Tim. Definitely a huge loss for the scientific community. And I did see a while back that there was an international symposium organized, showcasing his work for him to talk about his journey last year where more than 200, 250 people from around the globe actually attended that. That speaks volumes to the kind of impact he's had as an individual and impact he's had on the scientific side of things as well. Dr. Timothy Showalter: Yes. And we just had the second annual Feng Symposium the day before ASCO GU this year with, again, a great turnout and some great science highlighted, as well as a real focus on mentorship and team science and collaboration. Dr. Rafeh Naqash: Thank you so much for telling us all about that. Now going to what you guys published in JCO Precision Oncology, which is this article on using a biomarker approach to stratify non-metastatic prostate cancer using this artificial intelligence based H&E score. Could you tell us the background for what started off this project? And I see there is a clinical trial data set that you guys have used, but there's probably some background to how this score or how this technology came into being. So, could you superficially give us an idea of how that started? Dr. Timothy Showalter: Sure. So, the multimodal AI score was first published in a peer reviewed journal back in 2022 and the test was originally developed through a collaboration with the Radiation Therapy Oncology Group or Energy Oncology Prostate Cancer Research Team. The original publication describes development and validation of a risk stratification tool designed to predict distant metastasis and prostate cancer specific mortality for men with localized prostate cancer. And the first validation was in men who were treated with definitive radiation therapy. There have been subsequent publications in that context and there's a set of algorithms that have been validated in localized prostate cancer and there's a test that's listed on NCCN guidelines based on that technology. The genesis for this paper was really looking at extending that risk stratification tool that was developed in localized prostate cancer to see if it could one, validate in a non-metastatic castrate refractory prostate cancer population for patients enrolled on the SPARTAN trial. And two, whether there was a potential role for the test output in terms of predicting benefit from apalutamide for patients with non-metastatic prostate cancer. For patients who are enrolled on the SPARTAN study, almost 40% of them had H&E stain biopsy slide material available and were eligible to be included in this study. Dr. Rafeh Naqash: Going a step back to how prostate cancer, perhaps on the diagnostic side using the pathology images is different as you guys have Gleason scoring, which to the best of my knowledge is not necessarily something that most other tumor types use. Maybe Ki-67 is somewhat of a comparison in some of the neuroendocrine cancers where high Ki-67 correlates with aggressive biology for prognosis. And similarly high Gleason scores, as we know for some of the trainees, correlates with poor prognosis. So, was the idea behind this based on trying to stratify or sub-stratify Gleason scoring further, where you may not necessarily know what to do with the intermediate high Gleason score individual tumor tissues? Dr. Timothy Showalter: Well, yeah. I mean, Gleason score is a really powerful risk stratification tool. As you know, our clinical risk groupings are really anchored to Gleason scores as an important driver for that. And while that's a powerful tool, I think, you know, some of the original recognition for applying computer vision AI into this context is that there are likely many other features located in the morphology that can be used to build a prognostic model. Going back to the genesis of the discovery project for the multimodal AI model, I think Felix Feng would have described it as doing with digital pathology and computer vision AI what can otherwise be done with gene expression testing. You know, he would have approached it from a genomic perspective. That's what the idea was. So, it's along the line of what you're saying, which is to think about assigning a stronger Gleason score. But I think really more broadly, the motivation was to come up with an advanced complementary risk stratification tool that can be used in conjunction with clinical risk factors to help make better therapy recommendations potentially. So that was the motivation behind it. Dr. Rafeh Naqash: Sure. And one of the, I think, other important teaching points we try to think about, trainees of course, who are listening to this podcast, is trying to differentiate between prognostic and predictive scores. So, highlighting the results that you guys show in relation to the MMAI score, the digital pathology score, and outcomes as far as survival as well as outcomes in general, could you try to help the listeners understand the difference between the prognostic aspect of this test and the predictive aspect of this test? Dr. Timothy Showalter: So let me recap for the listeners what we found in the study and how it kind of fits into the prognostic and the predictive insights. So, one, you know, as I mentioned before, this is ultimately a model that was developed and validated for localized prostate cancer for risk stratification. So, first, the team looked at whether that same tool developed in localized prostate cancer serves as a prognostic tool in non-metastatic castrate-refractory prostate cancer. So, we applied the tool as it was previously developed and identified that about 2/3 of patients on the SPARTAN trial that had specimens available for analysis qualified as high risk and 1/3 of patients as either intermediate or low risk, which we called in the paper ‘non-high risk'. And we're able to show that the multimodal AI score, which ranges from 0 to 1, and risk group, was associated with metastasis free survival time to second progression or PFS 2 and overall survival. And so that shows that it performs as a prognostic tool in this setting. And this paper was the first validation of this tool in non-metastatic castrate-refractory prostate cancer. So, what that means to trainees is basically it helps you understand how aggressive that cancer is or better stratify the risk of progression over time. So that's the prognostic performance. Dr. Rafeh Naqash: Thank you for trying to explain that. It's always useful to get an example and understand the difference between prognostic and predictive. Now again, going back to the technology, which obviously is way more complicated than the four letter word MMAI, I per se haven't necessarily done research in this space, but I've collaborated with some individuals who've done digital pathology assessments, and one of the projects we worked on was TIL estimation and immune checkpoint related adverse events using some correlation and something that one of my collaborators had sent to me when we were working on this project as part of this H&E slide digitalization, you need color deconvolution, you need segmentation cell profiling. Superficially, is that something that was done as part of development of this MMAI score as well? Dr. Timothy Showalter You need a ground truth, right? So, you need to train your model to predict whatever the outcome is. You know, if you're designing an AI algorithm for Ki-67 or something I think you mentioned before, you would need to have a set of Ki-67 scores and train your models to create those scores. In this case, the clinical annotation for how we develop the multimodal AI algorithm is the clinical endpoints. So going back to how this tool was developed, the computer vision AI model is interpreting a set of features on the scan and what it's trying to do is identify high risk features and make a map that would ultimately predict clinical outcomes. So, it's a little bit different than the many digital pathology algorithms where the AI is being trained to predict a particular morphological finding. In this case, the ground truth that the model is trained to predict is the clinical outcome. Dr. Rafeh Naqash: Sure. And from what you explained earlier, obviously, tumors that had a high MMAI score were the ones that were benefiting the most from the ADT plus the applausive. Is this specific for this androgen receptor inhibitor or is it interchangeable with other inhibitors that are currently approved? Dr. Timothy Showalter: That's a great question and we don't know yet. So, as you're alluding to, we did find that the MMAI risk score was predictive for benefit from apalutamide and so it met the statistical definition of having a significant interaction p value so we can call it a predictive performance. And so far, we've only looked in this population for apalutamide. I think you're raising a really interesting point, which is the next question is, is this generalizable to other androgen receptor inhibitors? There will be future research looking at that, but I think it's too early to say. Just for summary, I think I mentioned before, there are about 40% of patients enrolled on the SPARTAN study had specimens available for inclusion in this analysis. So, the SPARTAN study did show in the entire clinical trial set that patients with non-metastatic castrate-refractory prostate cancer benefited from apalutamide. The current study did show that there seems to be a larger magnitude of benefit for those patients who are multimodal AI high risk scores. And I think that's very interesting research and suggests that there's some interaction there. But I certainly would want to emphasize that we have not shown that patients with intermediate or low risk don't benefit from apalutamide. I think we can say that the original study showed that that trial showed a benefit and that we've got this interesting story with multimodal AI as well. Dr. Rafeh Naqash: Sure. And I think from a similar comparison, ctDNA where ctDNA shows prognostic aspects, I treat people with lung cancer especially, and if you're ctDNA positive at a 3 to 4-month period, likely chances of you having a shorter disease-free interval is higher. Same thing I think for colorectal cancers. And now there are studies that are using ctDNA as an integral biomarker to stratify patients positive/negative and then decide on escalation/de-escalation of treatment. So, using a similar approach, is there something that is being done in the context of the H&E based stratification to de-intensify or intensify treatments based on this approach? Dr. Timothy Showalter: You're hitting right on the point in the most promising direction. You know, as we pointed out in the manuscript, one of the most exciting areas as a next step for this is to use a tool like this for stratification for prospective trials. The multimodal AI test is not being used currently in clinical trials of non-metastatic castrate-refractory prostate cancer, which is a disease setting for this paper. There are other trials that are in development or currently accruing where multimodal AI stratification approach is being taken, where you see among the high-risk scores, at least in the postoperative setting for a clinical trial that's open right now, high risk score patients are being randomized to basically a treatment intensification question. And then the multimodal AI low risk patients are being randomized to a de-intensification experimental arm where less androgen deprivation therapy is being given. So, I think it's a really promising area to see, and I think what has been shown is that this tool has been validated really across the disease continuum. And so, I think there are opportunities to do that in multiple clinical scenarios. Dr. Rafeh Naqash: Then moving on to the technological advancements, very fascinating how we've kind of evolved over the last 10 years perhaps, from DNA based biomarkers to RNA expression and now H&E. And when you look at cost savings, if you were to think of H&E as a simpler, easier methodology, perhaps, with the limitations that centers need to digitalize their slides, probably will have more cost savings. But in your experience, as you've tried to navigate this H&E aspect of trying to either develop the model or validate the model, what are some of the logistics that you've experienced can be a challenge? As we evolve in this biomarker space, how can centers try to tackle those challenges early on in terms of digitalizing data, whether it's simple data or slides for that matter? Dr. Timothy Showalter: I think there's two main areas to cover. One, I think that the push towards digitalization is going to be, I think, really driven by increasing availability and access to augmentative technologies like this multimodal AI technology where it's really adding some sort of a clinical insight beyond what is going to be generated through routine human diagnostic pathology. I think that when you can get these sorts of algorithms for patient care and have them so readily accessible with a fast turnaround time, I think that's really going to drive the field forward. Right now, in the United States, the latest data I've seen is that less than 10% of pathology labs have gone digital. So, we're still at an early stage in that. I hope that this test and similar ones are part of that push to go more digital. The other, I think, more interesting challenge that's a technical challenge but isn't about necessarily how you collect the data, but it certainly creates data volume challenges, is how do you deal with image robustness and sort of translating these tools into routine real-world settings. And as you can imagine, there's a lot of variation for staining protocols, intensity scanner variations, all these things that can affect the reliability of your test. And at least for this research group that I'm a part of that has developed this multimodal AI tool can tell you that the development is sophisticated, but very data and energy intensive in terms of how to deal with making a tool that can be consistent across a whole range of image parameters. And so that presents its own challenges for dealing with a large amount of compute time and AI cycles to make robust algorithms like that. And practically speaking, I think moving into other diseases and making this widely available, the size of data required and the amount of cloud compute time will be a real challenge. Dr. Rafeh Naqash: Thank you for summarizing. I can say that definitely, you know, this is maybe a small step in prostate cancer biomarker research, but perhaps a big step in the overall landscape of biomarker research in general. So definitely very interesting. Now, moving on to the next part of the discussion is more about you as a researcher, as an individual, your career path, if you can summarize that for us. And more interestingly, this intersection between being part of industry as well as academia for perhaps some of the listeners, trainees who might be thinking about what path they want to choose. Dr. Timothy Showalter: Sure. So, as you may know, I'm a professor at the University of Virginia and I climbed the academic ladder and had a full research grant program and thought I'd be in academia forever. And my story is that along the way, I kind of by accident ended up founding a medical device company that was called Advaray and that was related to NCI SBIR funding. And I found myself as a company founder and ultimately in that process, I started to learn about the opportunity to make an impact by being an innovator within the industry space. And that was really the starting point for me. About four years ago, soon after Felix Feng co-founded Artera, he called me and told me that he needed me to join the company. For those who were lucky to know Felix well, at that very moment, it was inevitable that I was going to join Artera and be a part of this. He was just so persuasive. So, I will say, you know, from my experience of being sort of in between the academic and industry area, it's been a really great opportunity for me to enter a space where there's another way of making an impact within cancer care. I've gotten to work with top notch collaborators, work on great science, and be part of a team that's growing a company that can make technology like this available. Dr. Rafeh Naqash: Thank you so much, Tim, for sharing some of those thoughts and insights. We really appreciate you discussing this very interesting work with us and also appreciate you submitting this to JCO Precision Oncology and hopefully we'll see more of this as this space evolves and maybe perhaps bigger more better validation studies in the context of this test. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Join us at eTown Hall as we revisit a show from 2019 featuring tattooed teddy-bear Timothy Showalter, who goes by the stage name Strand Of Oaks. Sharing the bill is singer-songwriter Anna Burch. Nick also interviews Murray Fisher of the Billion Oyster Project about the importance of oysters for clean water and storm mitigation. That's all this week on eTown!   Visit our Youtube Channel to see artist interviews, live recordings, studio sessions, and more! Be a part of the audience at our next recording: https://www.etown.org/etown-hall/all-events/ Your support helps us bring concerts, tapings and conversations to audiences while fostering connection through music, ideas and community. If you'd like to support eTown's mission to educate, entertain and inspire a diverse audience through music and conversation, please consider a donation: https://www.etown.org/get-involved/donate-orig/.  

I interviewed Dr. Timothy Showalter, chief medical officer of Artera, which has devised an AI tool that can read digital pathology slides to recommend appropriate treatment for patients with localized prostate cancer. Episode Resources Connect with Arundhati Parmar aparmar@medcitynews.com https://twitter.com/aparmarbb?lang=en https://medcitynews.com/ Connect with Timothy Showalter https://www.linkedin.com/in/tim-showalter-08616518/   Review, Subscribe and Share If you like what you hear please leave a review by clicking here Make sure you're subscribed to the podcast so you get the latest episodes. Click here to subscribe with Apple Podcasts Click here to subscribe with Spotify Click here to subscribe with Podbean Click here to subscribe with RSS

In 2021, in full pandemic tilt, Timothy Showalter aka Strand Of Oaks, released a brilliant  record in the vein of much of his stratospheric catalog called In Heaven (Dead Oceans) but decided not to tour on it, because that's what you didn't do during those heavy days; tour. Instead, he shut it all down. Stopped strumming and humming and stopped checking his emails and all other things that create anxiety for an artist who's been busting his ass for most of 20 years and who's making quite a dent in the music world with his intoxicating mix of Neil Youngian based songs and stories. There's always been an astral leaning, psychedelic connection to Strand of Oaks music, but for that moment it needed to cease, and all Tim Showalter wanted to do was paint. Not to mention, he was asked to join the cast of Mayans MC for 2 seasons, working with Edward James Olmos, something he'd never considered a possibility. The painting and acting paused, and the music started again. But this time he wasn't drawn to his guitar and the usual Youngian template. Instead he headed to his synthesizers and his long time engineer/producer/collaborator Kevin Ratterman (Elliot, Twin Limb) and rebirthed his muse in a different form, albeit one that continues to radiate what Tim does instinctively, move the listener. His new album Miracle Focus, is a fresh start and reflects his DIY ethic completely. It's still 100% Strand Of Oaks, long time fans will be relieved to know, but uses instruments that inspired him for this round of songs after the time off. Songs that give back what he's been living, Transendental Meditation, Yoga, Ram Dass and the feeling of joy that each moment creates, passes and recreates again infinitely. 

Spinning Out (another music podcast) We talk to artists about their favorite albums and go on wild tangents. This week on the pod we're joined by Timothy Showalter of Strand of Oaks and actor from the FX/Hulu show Mayans MC. We talked about the 2017 Alice Coltrane compilation album, "World Spirituality Classics Volume 1: The Ecstatic Music of Alice Coltrane Turiyasangitananda." We also chat about the concept of om, trying to have good energy, learning to speak the language of music. There's a new Strand of Oaks album out right now. It's called Miracle Focus -- Pick it up directly from Tim or from your local record store. https://strandofoaks.bandcamp.com/album/miracle-focus Subscribe to our Patreon here: www.patreon.com/spinningoutpod Follow us on social media -- twitter and instagram (@Spinningoutpod)

"I don't have stage fright, I have life fright." Indiana native Timothy Showalter -- the mind and voice behind the moniker Strand of Oaks -- has pulled no punches when it comes to combatting his own childhood trauma and lifelong anxieties through music. And while he says that touring and performing puts him in his most zen state, he has experienced a death or sorts with the guitar-centered music Strand of Oaks has done until now. His upcoming album Miracle Focus finds him piloting synthesizers and crafting, what he calls, "a manual for my life. A soundtrack to connection." And despite a drastic instrumental shift, the core of Miracle Focus is still within the hopeful sonic palette that Showalter is known for. On today's second visit to Vinyl Emergency, he also discusses having a song go #1 in Belgium, what got him kicked out of Moby's restaurant, and his recent TV role on the Sons of Anarchy spin-off, Mayans MC. Visit strandofoaks.net for social media, tour dates and to pre-order Miracle Focus before it drops June 7th.

Join us at eTown Hall as we revisit a show from 2019 featuring tattooed teddy bear Timothy Showalter--who goes by the stage name Strand Of Oaks, and singer-songwriter Anna Burch. Nick also interviews Murray Fisher of the Billion Oyster Project about the importance of oysters for clean water and storm mitigation.   That's all this week on eTown!   Visit our Youtube Channel to see artist interviews, live recordings, studio sessions, and more!   Be a part of the audience at our next recording: https://www.etown.org/etown-hall/all-events/

Een track x track special met Strand of Oaks. Een gesprek over het album In Heaven dat in 2021 uitkwam. Timothy Showalter vertelt over zijn creatieve proces in deze Shelter From The Storm aflevering met host Stijn Buist. De liedjes die je hoort in deze podcast kun je nog eens rustig terug luisteren in de playlist die je kan vinden via onze website: tivolivredenburg.nl/studio/podcast/shelter-from-the-storm/

Strand of Oaks' Timothy Showalter discusses his three year anniversary of sobriety, the "miracle music" that inspires him to create, the musical lessons he learned from Phish and more.

In our debut MAGNET Television Podcast, we interview Strand Of Oaks (a.k.a. Timothy Showalter). We just named Strand Of Oaks' seventh album, In Heaven, the best record of 2021. In this podcast, Showalter talks about the albums, songs and concerts that changed his life and inspired him to make music. --- Support this podcast: https://anchor.fm/magnet-magazine/support

Singer-guitarist Timothy Showalter took the trauma of his early twenties and transformed it into his solo project Strand of Oaks while he was still in Pennsylvania but it’s open been since he moved down to Austin that his style has fully flourished. Following the release of his eighth album In Heaven back at the beginning […]

We had a beautiful conversation with American singer-songwriter Timothy Showalter, better known as Strand of Oaks. Ever since his first album 'Leave Ruin' in 2009  Showalter has continued to release albums, evolving and developing his craft along the way, the most recent being  'In Heaven'. We also spoke about taking up painting, a jazz approach to the album, quitting alcohol, not wanting to drag people down, being proud of his own artistry, support from his wife and My Morning Jacket, breaking a generational cycle, human connectivity and so much more. It honestly was an absolute joy to talk with Tim again. I hope you enjoy it as well!Interview by: Robin HignellSupport the show (https://www.patreon.com/FaceCulture)

The JamBase Podcast 'Cluster Flies' series features a deep dive into Phish's song “Bug” and an interview with Timothy Showalter of Strand Of Oaks who covered the song for the project.

Hope you're enjoying the new season of Aquarium Drunkard's Transmissions. Here's a good one from the archives, a favorite of Timothy Showalter of Strand of Oaks a roundtable talk with three lifers: Howe Gelb, Robyn Hitchcock, and Steve Wynn. The three share similar paths through scenes and the industry, their paths are shared but divergent, and there’s a spiritual unity at work even in their differences. With his band Giant Sand, Howe Gelb pens strange, dusty songs about love and the desert. Both solo and with his Paisley Underground pioneering band the Dream Syndicate, Wynn composes driving minimalist rock sagas (a recent 11-disc boxset documents much of his range) . And after emerging from the UK punk scene with the Soft Boys, Robyn Hitchcock has embarked on a career full of wry and funny songs that skewer pop conventions. We spoke in August of 2018 when they performed at HOCO Fest in Tucson, Arizona, a place where they all share considerable history. This interview was recorded at the KXCI studio at the historic Hotel Congress. Please enjoy this one from the vault.

Timothy Showalter, who leads the folk-rock band Strand of Oaks describes how hearing David Bowie's "Lazarus" at the end of the recording process helped him see how powerful documenting dark times could be.

Timothy Showalter, who leads the folk-rock band Strand of Oaks describes how hearing David Bowie's "Lazarus" at the end of the recording process helped him see how powerful documenting dark times could be.

Travel to Record Store Day with us as we explore Atlanta’s Criminal Records, a locally owned and independently operated record, comic store and more, located in Little Five Points. Learn about the store’s iconic name and its evolution over the years with founder Eric Levin. Listen to a live in-store performance by Timothy Showalter from Strand Of Oaks. Meet the customers that are bringing vinyl back. --- Support this podcast: https://anchor.fm/peach-and-prosperity/support

In episode four, the guys tackle Strand of Oak’s first album Leave Ruin. Released in 2009, this project revolves around front man, and only band member at the time, Timothy Showalter’s devastatingly personal narrative about loss and heartbreak. Forget Justin Vernon breaking up with his girlfriend and moving to a cabin in the woods. Prior to the release of this album, Timothy had his high school sweetheart break off their engagement, literally saw his house burn down to the ground, and was left with virtually nothing but the ashes. Forced to sleep on park benches as he coped with the loss, he took that grief and anguish, and transformed it into the album that we are discussing today.

t. For this episode, AD’s Jason P. Woodbury sat down with Timothy Showalter of Indiana’s Strand of Oaks to discuss the band’s latest album, Hard Love, which melds Showalter’s love of dub reggae production with heartland rock and the big beat sound of Creation Records’ heyday.

With his previous record, Timothy Showalter sought to look inward. On his latest LP as Strand of Oaks, Hard Love, Showalter is looking outward with his most expansive and expressive songs to date. Opening with the crushing, lengthy, and affecting “Taking Acid and Talking To My Brother”, the Philadelphia group's latest session is a stunning performance of four Hard Love tracks and a discussion between Kevin Cole and Showalter on how making shows sacred led Strand of Oaks to its next chapter. Recorded 3/1/2017 - 4 songs: Taking Acid and Talking To My Brother, Radio Kids, Rest Of It, EverythingSupport the show: https://www.kexp.org/donateSee omnystudio.com/listener for privacy information.

Timothy Showalter -- the voice and mind behind Strand of Oaks -- describes himself as a "smiling, sweaty, straight-out-of-a-river wild man" this week, and the vibrant album cover of this year's "Hard Love" encapsulates his aura so well, it nearly jumps off the shelf. His infatuation with vinyl and music in general is contagious and vast, expressing his adoration in this episode for anyone from "Weird Al" Yankovic to Endless Boogie. Today, we also discuss the crazy night that led to the cover photo for "Hard Love," why having his face on his album covers plays into his joy of digging for vinyl, what some of his discography is going for online (and why he won't buy anything on vinyl over the internet), what the best sounding album in his collection is, loaning Basic Cable Band leader Jimmy Vivino his guitar when Strand of Oaks recently played Conan, his obsession with dub music, whether one can truly be present while listening to music alone, and much more!  Visit StrandOfOaks.net for tour dates, social media, etc.  

Timothy Showalter is the first guest in the Forward Podcast new studio. The leader of Strand of Oaks talked about being fearless versus reckless, working as a school teacher and what he learned opening up for the likes of My Morning Jacket, Ryan Adams and Jason Isbell. Tim also broke in the new studio by playing three songs including a cover of Used Cars by Bruce Springsteen.

Timothy Showalter, the leader of this Philadelphia psych-rock-folk project, sits down to talk about growing up in small-town Indiana, how the radio shaped his sound, and learning how to maintain a private and public persona.

Strand of Oaks frontman Timothy Showalter talks about how he felt before recording his latest record, "HEAL," and how the record helped him get through it. The Sklar Brothers, Randy and Jason, take us into the strange nexus of comedy, music, and sports. We'll also call dibs on the showeroke. Yes, I said showeroke.

Timothy Showalter from Strand Of Oaks joins the DTFH and injects us with a sweet blast of pure unfiltered love.  Also a special announcement regarding the Christ Simulator.

This week on The One You Feed we have Timothy Showalter from Strand of Oaks. Strand of Oaks aka Timothy Showalter just released one of the years best records. Heal has been celebrated by NPR, Pitchfork, Mojo and Uncut among many others. It's one of our favorite records of the year. The story behind Heal: "From the first bars of HEAL, the exhilarating melodic stomp of 'Goshen '97' puts you right into Tim Showalter's fervent teenage mindset. We find him in his family's basement den in Goshen, IN, feeling alienated but even at 15 years old, believing in the alchemy and power of music to heal your troubles. "The record is called HEAL, but it's not a soft, gentle healing, it's like scream therapy, a command, because I ripped out my subconscious, looked through it, and saw the worst parts. And that's how I got better." HEAL embodies that feeling of catharsis and rebirth, desperation and euphoria, confusion and clarity. It is deeply personal and unwittingly anthemic.Showalter was on tour, walking home on a mild autumn night in Malmo, Sweden, when he first felt the weight of the personal crisis that would ignite him to write HEAL. "It was a culmination of pressure," Showalter recalls. "My marriage was suffering, I'd released a record I was disappointed in, I didn't like how I looked or acted...so I'd gone on tour, I was gone about two years! I didn't take time to think about failure, but I knew I was going deeper and deeper...I was thinking, I have this life, but it's not my life, I haven't done it right..."When Showalter returned, he wrote 30 songs in three weeks, a process that proved difficult, but cathartic and at times invigorating. Previous Strand Of Oaks records were more skeletal, raw examples of folk-rooted Americana with occasional rock and electronic currents, that have now come to the fore. HEAL is a bold new beginning, with a thrilling full-tilt sound that draws on Showalter's love of '70s, '80s and '90s rock and pop, with the singer and guitarist playing the intense valedictory confessor. In This Interview Tim and I Discuss... The One You Feed parable. The great success of his new record. The saddest line on his new record. The importance of feeling all of our emotions, not just the good ones. How hard it is to write uplifting music that isn't cheesy. Disliking ironic music. The redemptive power of rock and roll. How we care less about what people think as we age. The power of being our authentic selves. Becoming who we are. Avoiding the victim/villain mindset. Jason Molina of Songs:Ohia. Fighting the dark times. Strand of Oaks Links Strand of Oaks homepage Buy Heal on Amazon Strand of Oaks on Twitter Strand of Oaks on Facebook Strand of Oaks playlist on YouTube Some of our most popular interviews you might also enjoy: Kino MacGregor Mike Scott of the Waterboys Todd Henry- author of Die Empty Randy Scott Hyde See omnystudio.com/listener for privacy information.